Interaction index and different methods for determining drug interaction in combination therapy

Journal of Biopharmaceutical Statistics

Volumn 17, Issue 3, 2007, Pages 461-480

  Lee, J J ^a   Kong, M ^b   Ayers, G D ^c   Lotan, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antagonism; Drug interaction; Loewe additivity model; Response surface model; Synergy

Indexed keywords

4 HPR; ANTINEOPLASTIC AGENT; LONAFARNIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COMBINATION CHEMOTHERAPY; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; LOEWE ADDITIVITY MODEL; MATHEMATICAL ANALYSIS; PRIORITY JOURNAL; RESPONSE SURFACE METHOD;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CONFIDENCE INTERVALS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; REPRODUCIBILITY OF RESULTS;

EID: 34247897031     PISSN: 10543406     EISSN: 15205711     Source Type: Journal    
DOI: 10.1080/10543400701199593     Document Type: Article

References (33)

1. Bachmann, K. A., Ghosh, R. (2001). The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Current Drug Metabolism 2:299-314.
2. Berenbaum, M. C. (1989). What is synergy? Pharmacological Reviews 41:93-141.
3. Bickel, P. J., Doksum, K. A. (2001). Mathematical Statistics: Basic Ideas and Selected Topics. Vol. 1. Prentice Hall: New Jersey.
4. Bliss, C. I. (1939). The toxicity of poisons applied jointly. Annals of Applied Biology 26:585-615.
5. Carter, W. H. Jr., Gennings, C., Staniswalis, J. G., Cambell, E. D., White, K. L. Jr. (1988). A statistical approach to the construction and analysis of isobolograms. Journal of American College Toxicology 7:963-973.
6. Chou, T. C., Talalay, P. (1984). Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation 22:27-55.
7. Chun, K. H., Lee, J. J., Ayers, G. D., Lotan, R. (2003). Synergistic induction of apoptosis in human head and neck squamous cell carcinoma (HNSCC) cell lines by the combination of the synthetic retinoid 4HPR and the farnesyltransferase inhibitor SCH66336. Proceedings of American Association for Cancer Research 44.
8. Curran, W. J. Jr. (2003). Evolving chemoradiation treatment strategies for locally advanced non-small-cell lung cancer. Oncology (Huntingt) 17(12 Suppl 13):7-14.
9. Drebler, V., Muller, G., Suhnel, J. (1999). CombiTool-A new computer program for analyzing combination experiments with biologically active agents. Computers and Biomedical Research 32:145-160.
10. Evans, T. L. (2004). Highlights from the tenth world conference on lung cancer. Oncologist 9(2):232-238.
11. Finney, D. J. (1971). Probit Analysis. Cambridge: Cambridge University Press.
12. Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., Sorger, P. (2006). Systems biology and combination therapy in the quest for clinical efficacy. Nature Chemical Biology 2(9):458-466.
13. Greco, W. R., Park, H. S., Rustum, Y. M. (1990). Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-β-D-arabinofuranosylcytosine. Cancer Research 50:5318-5327.
14. Greco, W. R., Bravo, G., Parsons, J. C. (1995). The search of synergy: a critical review from a response surface perspective. Pharmacological Reviews 47(2):331-385.
15. Greco, W. R., Unkelbach, H. D., Poch, G., Suhnel, J., Kundi, M., Bodeker, W. (1992). Consensus on concepts and terminology for combined-action assessment: the Saariselka Agreement. Arch. Complex Environ. Stud. 4:65-69.
16. Herbst, R. S. (2005). Role of novel targeted therapies in the clinic. British Journal of Cancer 92(Suppl 1):S21-27.
17. Hill, A. V. (1910). The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. The Journal of Physiology 40:iv-vii.
18. Holford, N. H. G., Sheiner, L. B. (1981). Understanding the dose-effect relationship: clinical application of pharnacokinetic-Pharmacodynamic models. Clinical Pharmcokinetics 6:429-453.
19. Jonker, D. M., Visser, S. A. G., van der Graaf, P. H., Voskuyl, R. A., Danhof, M. (2005). Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacology and Therapeutics 106:1-18.
20. Kong, M., Lee, J. J. (2006a). A general response surface model with varying relative potency for assessing drug interactions. Biometrics 62:986-995.
21. Kong, M., Lee, J. J. (2006b). A semiparametric response surface model for assessing drug interactions. (Submitted).
22. Lee, J. J., Kong, M. (2006). A confidence interval for interaction index for assessing multiple drug interaction. (Submitted).
23. Machado, S. G., Robinson, G. A. (1994). A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Statistics in Medicine 13:2289-2309.
24. Martinez-Irujo, J. J., Villahermosa, M. L., Mercapide, J., Cabodevilla, J. F., Santiago, E. (1998). Analysis of the combined effect of two linear inhibitors on a single enzyme. Biochemical Journal 329:689-698.
25. Morgan, B. J. T. (1992). Analysis of Quantal Response Data. Chapman and Hall.
26. Niyazi, M., Belka, C. (2006). Isobologram analysis of triple therapies. Radiation Oncology Oct 17:1-39.
27. Plackett, R. L., Hewlett, P. S. (1952). Quantal responses to mixtures of poisons. Journal of the Royal Statistical Society B 14:141-163.
28. Plummer, J. L., Short, T. G. (1990). Statistical modeling of the effects of drug combinations. Journal of Pharmacological Methods 23:297-309.
29. Sharma, P. L., Nurpeisov, V., Hernandez-Santiago, B., Beltran, T., Schinazi, R. F. (2004). Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Current Topics in Medicinal Chemistry 4(9):895-919.
30. Straetemans, R., O'Brien, T., Wouters, L., Dun, J. V., Janicot, M., Bijnens, L., Burzykowski, T., Aerts, M. (2005). Design and analysis of drug combination experiments. Biometrical Journal 47(3):299-308.
31. Tallarida, R. J. (2000). Drug Synergism and Dose-Effect Data Analysis. New York: Chapman and Hall.
32. Tan, M., Fang, H., Tian, G., Houghton, P. J. (2003). Experimental design and sample size determination for testing synergism in drug combination studies based on uniform measures. Statistics in Medicine 22:2091-2100.
33. Webb, J. L. (1963). Enzyme and Metabolic Inhibitors. New York: Academic Press.